Christopher Sullivan

Chief Financial Officer and principal financial officeratAvalo Therapeutics· In proxies 2022–2024

Pay in FY2024+382% from the year before · Avalo Therapeutics stock -18.4% the same year

Christopher Sullivan was paid $2.9M in FY2024 (Dec), up 382%. Avalo Therapeutics stock fell 18.4% that year.

Pay$100 in the stock at the end of FY21 → $0

Pay is from the Summary Compensation Table of each Avalo Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

AVTX
Avalo TherapeuticsPublic company · 4 yr
- Chief Financial Officer and principal financial officer2022 – Present · 4 yrStock in role -100%

Roles come from the proxy statements of each company.

Activity

Pay
Avalo Therapeutics CFO pay rose 382% to $2.9M. The stock fell 18% in FY2024 (Dec).
DEF 14AMay 1, 2025
Pay
Avalo Therapeutics CFO pay fell 21% to $607.6K. The stock fell 99% in FY2023 (Dec).
DEF 14AJun 27, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?